Ching‐Yuan Kuo

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients

Sung‐Nan Pei, Chien‐Hung Chen, Chuan–Mo Lee et al. · Annals of Hematology · 2009 · 211 citations

Hepatology, Viral Hepatitis, Immunology +7

Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy

Sung‐Nan Pei, Ming‐Chun Ma, Ming‐Chung Wang et al. · Annals of Hematology · 2012 · 91 citations

Lymphoid Neoplasia, Hepatology, Viral Hepatitis +7

Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations

Guo‐Wang Lin, Caigang Xu, Kexin Chen et al. · The Lancet Oncology · 2019 · 68 citations

Genome-wide Association Study, Lymphoid Neoplasia, Disease Susceptibility +13

Clinical features and risk factors for mortality in Aeromonas bacteremic adults with hematologic malignancies.

Moan-Shane Tsai, Ching‐Yuan Kuo, Ming‐Chung Wang et al. · PubMed · 2006 · 57 citations